TuHURA Biosciences, Inc. (NASDAQ:HURA) Stock Has Consensus Target Price of $9.00

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $9.00.

A number of analysts have recently commented on HURA shares. Citizens Jmp restated a “market outperform” rating and set a $9.00 target price on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Friday, July 17th.

Institutional Trading of TuHURA Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of TuHURA Biosciences during the second quarter valued at $1,615,000. Apollon Wealth Management LLC raised its position in shares of TuHURA Biosciences by 17.7% in the 1st quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock worth $283,000 after purchasing an additional 23,717 shares during the last quarter. Cetera Investment Advisers purchased a new position in shares of TuHURA Biosciences in the 1st quarter worth about $251,000. Bank of New York Mellon Corp bought a new position in TuHURA Biosciences in the 2nd quarter worth about $285,000. Finally, WealthShield Partners LLC bought a new position in TuHURA Biosciences in the 1st quarter worth about $164,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Price Performance

HURA stock opened at $1.96 on Wednesday. TuHURA Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $3.43. The business’s 50 day moving average price is $2.10 and its two-hundred day moving average price is $2.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.18 and a current ratio of 0.18. The company has a market capitalization of $124.91 million, a price-to-earnings ratio of -3.63 and a beta of -0.21.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. As a group, analysts forecast that TuHURA Biosciences will post -0.55 earnings per share for the current fiscal year.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ:HURA) is a clinical-stage biotechnology company focused on developing therapies designed to overcome immune suppression in the tumor microenvironment and improve responses to cancer treatment. The company’s research is centered on immuno-oncology approaches intended to stimulate both innate and adaptive immune responses against tumors.

TuHURA’s lead program, IFx-2, is an investigational intratumoral immunotherapy and cancer vaccine candidate designed to reprogram the tumor environment and promote an immune response.